<< Back To Search

Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial


Third Opinion Trial Synopsis:
Doctors are testing a new treatment called daratumumab for patients with multiple myeloma. This treatment uses something called monoclonal antibodies to try and kill any cancer cells left in the body after chemotherapy. It's only in the second stage of testing, but it could be promising for patients who need more options to fight their cancer.
*Third Opinion AI Generated Synopsis

Trial Summary
This phase II trial studies how well daratumumab after a stem cell transplant works in treating patients with multiple myeloma. Monoclonal antibodies, such as daratumumab, may kill cancer cells that are left after chemotherapy.

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?